目的 探讨前列舒通胶囊联合普适泰片治疗慢性前列腺炎的临床疗效。方法 选取2021年1月—2022年12月如皋市人民医院收治的100例慢性前列腺炎患者，根据计算机随机排列法将所有患者分为对照组和治疗组，每组各50例。对照组饭后口服普适泰片，1片/次，2次/d。治疗组在对照组基础上口服前列舒通胶囊，3粒/次，3次/d。两组连续治疗3个月。观察两组的临床疗效，比较两组国立卫生研究院慢性前列腺炎症状指南（NIH-CPSI）评分、最大尿流率、残余尿量以及血清中总前列腺特异性抗原（TPSA）、白细胞介素-8（IL-8）、白细胞介素-2（IL-2）的水平和前列腺液中白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、单核细胞趋化蛋白-1（MCP-1）水平。结果 治疗后，治疗组的总有效率92.00%明显高于对照组的总有效率76.00%，差异有统计学意义（P＜0.05）。治疗后，治疗组疼痛不适、尿频尿急、尿不尽消失时间均明显短于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的NIH-CPSI评分低于治疗前（P＜0.05），且治疗组NIH-CPSI评分较对照组更低（P＜0.05）。治疗后，两组前最大尿流率高于治疗前，残余尿量低于治疗前（P＜0.05）；治疗后，治疗组最大尿流率高于对照组，残余尿量低于对照组（P＜0.05）。治疗后，两组血清TPSA、IL-8、IL-2水平均低于治疗前（P＜0.05）；治疗后，治疗组患者的血清TPSA、IL-8、IL-2水平低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者前列腺液IL-1β、IL-6、MCP-1水平低于治疗前（P＜0.05）；治疗后，治疗组患者前列腺液IL-1β、IL-6、MCP-1水平低于对照组（P＜0.05）。结论 前列舒通胶囊联合普适泰片治疗慢性前列腺炎的疗效确切，可显著减轻临床症状，控制病情进展，进一步降低炎症反应。

Objective To investigate the clinical effect of Qianlie Shutong Capsules combined with Prostat Tablets in treatment of chronic prostatitis. Methods Patients (100 cases) with chronic prostatitis in the People’s Hospital of Rugao from January 2021 to December 2022 were divided into control group and treatment group according to the computer random arrangement method, and each group had 50 cases. Patients in the control group were po administered with Prostat Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Qianlie Shutong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and NIH-CPSI scores, maximum urine flow rate, residual urine volume, the serum levels of TPSA, IL-8, and IL-2, the levels of IL-1β, IL-6, and MCP-1 in prostatic fluid of two groups were compared. Results After treatment, the total effective rate of 92.00% in the treatment group was significantly higher than 76.00% in the control group, with statistically significant difference (P< 0.05). After treatment, disappearance time of pain and discomfort, frequent and urgent urination, and inexhaustible urine in the treatment group was lower than those in the control group, with a statistically significant difference (P < 0.05). After treatment, NIH-CPSI scores of two groups were lower than before treatment (P< 0.05), and NIH-CPSI scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the maximum urine flow rate in two groups was higher than before treatment, but the residual urine volume in two groups was lower than before treatment (P < 0.05). After treatment, the maximum urine flow rate in the treatment group was higher than that in the control group, but the residual urine volume in the treatment group was lower than that in the control group (P < 0.05). After treatment, the serum levels of TPSA, IL-8, and IL-2 in two groups were lower than before treatment (P < 0.05). After treatment, the serum levels of TPSA, IL-8, and IL-2 in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of IL-1β, IL-6, and MCP-1 in the prostatic fluid of two groups were lower than before treatment (P < 0.05). After treatment, the levels of IL-1β, IL-6, and MCP-1 in the prostate fluid of the treatment group were lower than those of the control group (P < 0.05). Conclusion Qianlie Shutong Capsules combined with Prostat Tablets has definite efficacy in treatment of chronic prostatitis, which can significantly reduce clinical symptoms, control the progression of the disease, and further reduce the inflammatory reaction.

R983

江苏省卫生健康委科研课题（H2018091）